The Journal of the American Dental Association
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Am Dent Assoc, Vol 137, No 4, 441.
© 2006 American Dental Association

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lasser, A. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lasser, A. J.

LETTERS

MORE ABOUT BON

In the December JADA cover story by Dr. Cesar Migliorati and colleagues, "Managing the Care of Patients With Bisphosphonate-Associated Osteonecrosis: An American Academy of Oral Medicine Position Paper" ( JADA 2005; 136:1658–68 ) the authors state, "Bone turnover becomes profoundly suppressed and, over time, the bone shows little physiologic remodeling.1,2 The bone becomes brittle and unable to repair physiologic microfractures that occur in the human skeleton with daily activity.3,4 In the oral cavity, the maxilla and mandible are subjected to constant stress from masticatory forces.2 Thus, it is expected that physiologic microdamage and microfractures occur daily in the oral cavity. It is theorized that in a patient taking a bisphosphonate, the resulting microdamage is not repaired, setting the stage for oral osteonecrosis to occur.

"The need for repair and remodeling is increased greatly when there is infection in the maxilla or mandible, and/or when an extraction is performed. In some patients using bisphosphonates, the bone is unable to meet these increased needs, both because of its reduced ability to remodel and turn over and because of hypovascularity, which results in osteonecrosis."5,6

This article, and the two related cover articles,7,8 prompt a few questions that I hope the authors will be able to address.

It would seem advisable to tell our patients to stay away from things that require repetitive chewing, such as gum. Additionally, patients should reduce chewing exceptionally hard foods such as nuts and raw carrots. Do you feel this is a valid area of investigation or implementation?

Do you feel that we should put this group of patients on chlorhexidine mouthrinse therapy before the potential onset of a problem, instead of after the problem occurs? The articles presented indicate there is a six- to 18-month period, on average, before a problem starts, depending on which of the two intravenous drugs are used. Should we, therefore, at six months begin prescribing a rinse when the patient is taking pamidronate, and at 18 months for those taking zoledronic acid?


   REFERENCES
 TOP
 REFERENCES
 
  1. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005;90: 1897–9.[Free Full Text]

  2. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294–301.[Abstract/Free Full Text]

  3. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003; 349:457–63.[Free Full Text]

  4. Marini JC. Do bisphosphonates make children’s bones better or brittle? N Engl J Med 2003;349:423–6.[Free Full Text]

  5. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bisphossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682–9.[Medline]

  6. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104: 83–93.[Medline]

  7. Markiewicz MR, Margarone JE 3rd, Campbell HJ, Aguirre A. Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. JADA 2005;136: 1669–74.

  8. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. JADA 2005;136:1675–81.



Allan J. Lasser, DDS

Livonia, Mich.



This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lasser, A. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lasser, A. J.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS